GleamWall
中文EN

SVRA Savara Inc

Pharmaceutical Preparations · Nasdaq · SEC CIK 1160308 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-32.1%
TTM EPS YoY-13.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-151.0%
ROA-102.9%
ROIC (approx.)-114.7%
Asset turnover—

Leverage & solvency

Liabilities / assets30.8%
Debt / equity0.28x
Current ratio8.55x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.85x
Accruals ratio-15.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$24.95M$21.95M$23.40M$20.90M$20.59M$20.75M$19.16M$23.29M
SG&A expense$18.54M$18.99M$15.57M$12.53M$9.63M$10.65M$9.25M$7.85M
Operating income-$43.54M-$40.97M-$38.99M-$33.42M-$30.25M-$31.44M-$28.43M-$31.17M
Pretax income——————-$26.64M—
Net income-$42.99M-$40.23M-$37.28M-$32.24M-$29.56M-$30.40M-$26.64M-$29.04M
EBITDA-$43.49M-$40.94M-$38.97M-$33.43M-$30.22M-$31.41M-$28.41M-$31.14M
EPS (basic)-0.17-0.16-0.15—-0.14-0.14-0.12—
EPS (diluted)-0.17-0.16-0.15—-0.14-0.14-0.12—
Weighted avg. shares (diluted)254.22M253.57M253.28M—216.46M216.43M216.15M—
Balance sheet
Cash & equivalents$29.81M$41.80M$38.79M$33.18M$16.28M$17.44M$19.56M$15.13M
Short-term investments$99.84M$131.23M$163.98M$202.52M$108.11M$129.01M$152.94M$181.20M
Current assets$142.12M$178.32M$209.26M$241.62M$128.20M$150.99M$177.44M$202.13M
PP&E, net$716,000$641,000$130,000$100,000$85,000$119,000$138,000$165,000
Total assets$155.93M$192.14M$221.65M$253.44M$140.92M$163.76M$189.32M$212.88M
Current liabilities$16.63M$17.60M$15.54M$20.40M$16.76M$13.63M$11.90M$14.72M
Short-term debt$0$0$0$0$0$0$0$0
Long-term debt$30.24M$30.11M$30.07M$29.91M$29.78M$29.65M$29.52M$26.62M
Total debt$30.24M$30.11M$30.07M$29.91M$29.78M$29.65M$29.52M$26.62M
Total liabilities$48.08M$48.48M$45.61M$50.30M$46.54M$43.28M$41.47M$41.43M
Shareholders' equity$107.85M$143.66M$176.04M$203.13M$94.39M$120.48M$147.85M$171.45M
Net debt$430,000-$11.69M-$8.72M-$3.27M$13.50M$12.22M$9.97M$11.49M
Shares outstanding205.54M205.40M204.92M204.57M—172.85M172.70M172.42M
Cash flow statement
Operating cash flow-$42.46M-$29.75M-$33.05M-$25.06M-$22.53M-$26.26M-$27.19M-$23.28M
Capital expenditure$353,000$222,000$54,000$2,000$2,000$15,000$3,000-$9,000
Free cash flow-$42.82M-$29.97M-$33.10M-$25.06M-$22.53M-$26.28M-$27.19M-$23.27M
Investing cash flow$31.01M$32.60M$38.78M-$93.56M$21.47M$24.33M$29.33M$17.89M
Financing cash flow-$385,000$189,000-$195,000$135.56M-$23,000-$49,000$2.32M-$843,000
Depreciation & amortization$56,000$28,000$24,000-$11,000$36,000$34,000$30,000$32,000
Stock-based compensation$7.83M$7.76M$10.73M$5.36M$3.42M$2.67M$2.97M$3.04M

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.